Claritin Articles
Schering-Plough profits beat forecasts
21 April 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
S-P profit falls 21%, still up on predictions
27 October 2008
Shionogi's Crestor boosts fiscal 2007
2 June 2008
No to Merck & Co/S-P combo allergy drug
5 May 2008
Rx-to-OTC switching making comeback
21 April 2008
Mylan seeks more generic market share
7 April 2008
S-P's 4th-qtr 2007 results hit by Organon buy
18 February 2008
Japan stock market week to Jan 28, 2008
4 February 2008
Crestor boosts Shionogi 1st-qtr fiscal sales 8.7%
6 August 2007
S-P's 2nd-quarter 2007 EPS doubles to $0.34
30 July 2007
Schering-Plough 1st-qtr profits leap 55%
30 April 2007
Ranbaxy gets US approval for generic loratadine
16 April 2007
S-P subsidiary fined $435.0M
29 January 2007
S-P's 3rd-qtr 2006 net income improves
30 October 2006
Schering-Plough settles investigation and agrees to pay $435 million
4 September 2006
Andrx' 4th-qtr 2005 income drops 16%
27 March 2006
Japan stock market week to Mar 13, 2006
20 March 2006
Shionogi's fiscal half-year revenue up 1.6%
12 December 2005
SP's Claritin "clears your head," says study
5 December 2005
Perrigo's fiscal-2005 sales jumps 14%
19 September 2005
Good 1st-qtr results for Shionogi
22 August 2005
Schering-Plough expands in Asia Pacific
18 July 2005
Schering-Plough back in profit for 1st-qtr
22 April 2005
Schering-Plough aims for 100B yen sales in Japan by 2010
18 April 2005
Spring allergies impact attention span, memory
4 April 2005
$1B sales milestone for OTC Claritin
4 April 2005
Shionogi's 3rd-qtr sees sales drop 2.9%
21 February 2005
Rx-to-OTC switching motives queried
17 January 2005
S-P to pay $6M+ to Pa Medicaid program in Claritin pricing case
10 January 2005
Taro Pharma gains FDA OK for generic loratadine syrup
30 August 2004
Shionogi profits up on plan, sales decline
23 August 2004
Stock Commentary - New York
12 July 2004
Shionogi's full-year income plunges 62.7%
14 June 2004
Tokyo pharma stocks - week to May 24
31 May 2004
Tokyo pharma stocks - week to April 26
3 May 2004
Shionogi sales in line with forecasts
16 February 2004
Intron slump, charges lead to S-P loss
2 February 2004
Tokyo pharma stocks - week to Jan 19
26 January 2004
Popularity of OTC allergy products puts pressure on US Rx prices
26 January 2004
Schering-Plough settles Claritin-D patent litigation with Impax
3 November 2003
S-P Claritin woes hit third quarter sales
27 October 2003
S-P Claritin woes hit third quarter sales
27 October 2003
US doctors' "key" role in OTC drug sales
29 September 2003
US insurers move on generics, OTCs
22 September 2003
Schering-Plough cash-flow questions
18 August 2003
Tokyo pharma stocks - week to August 11
18 August 2003
Generics push S-P profits down 71%
28 July 2003
Italy: Rx prices "70.4% higher due to patents"
14 July 2003
US generics approvals for Teva and B&L
16 June 2003
S-P set to face criminal charges in USA?
9 June 2003
Cost-cutting reaps dividends at Shionogi
2 June 2003
S-P's new CEO sets out turnaround plan
19 May 2003
Tokyo pharma stocks - week to May 5
12 May 2003
$1.1 bill buyback at Aventis as profits fall
5 May 2003
US FDA "has authority for Rx-OTC switches"
5 May 2003
S-P, Novartis link up on asthma product
21 April 2003
California directs HMOs over switched drugs
7 April 2003
Schering-Plough gives $0.75-$0.85 EPS guide
17 March 2003
Stock Commentary - Europe
10 March 2003
S-P gets patent extension for Clarinex
3 March 2003
Leiner to tackle private-label OTC loratadine market
10 February 2003
Impax' generic Claritin cleared in USA
10 February 2003
Stock Commentary - Week to January 27 - New York
3 February 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
Looming Claritin rivals cut S-P shares 7%
3 February 2003
Claritin switch hits S-P, sales down 4% in 2002
3 February 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
S-P lowers forecast as Claritin rivalry bites
20 January 2003
Update - Wyeth gets final OTC Claritin approval
6 January 2003
Wyeth gets final OTC Claritin approval
6 January 2003
Claritin generics "will cut US Rx market 15%"
19 August 2002
S-P to appeal Claritin patent ruling
19 August 2002
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
